8-K: Neuronetics to Acquire Greenbrook TMS, Expanding Access to NeuroStar Therapy

Neuronetics is set to acquire Greenbrook TMS, aiming to amplify brand awareness and provide enhanced services to NeuroStar practices.

Summary

• Neuronetics, the manufacturer of NeuroStar TMS, is acquiring Greenbrook TMS, a large TMS provider with 120 locations in 18 states.
• The acquisition aims to leverage the strengths of both companies to increase brand awareness and provide more value to NeuroStar practices.
• The goal is to transform Greenbrook locations into NeuroStar centers, increasing patient recognition of the NeuroStar brand.
• The acquisition will allow Neuronetics to market NeuroStar more broadly, similar to how Starbucks has expanded its brand recognition.
• The combined entity will focus on addressing challenges faced by NeuroStar practices, such as reimbursement, billing, and cash flow.
• Neuronetics plans to leverage Greenbrook's existing payer contracts to secure better reimbursement rates for all NeuroStar providers.
• The acquisition will also provide access to Greenbrook's insurance billing services and centralized call center.
• Greenbrook's experience in Spravato and medication management will be shared with NeuroStar practices.
• The acquisition is expected to close by the end of 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook due to the strategic acquisition and its potential benefits for both the company and its customers. The management's confidence and the focus on addressing customer pain points contribute to the positive sentiment.

Positives

• The acquisition will increase brand awareness for NeuroStar, making it more recognizable to patients.
• NeuroStar practices will benefit from improved reimbursement rates through Greenbrook's payer contracts.
• Practices will gain access to Greenbrook's insurance billing services, reducing administrative burdens.
• A centralized call center will be available to help practices manage patient inquiries.
• Referral networks will be expanded through Greenbrook's existing relationships with community psychiatrists and primary care physicians.
• Practices will receive training on incorporating medication management and Spravato into their services.
• The Better Me Provider Program will continue to support practices, with Greenbrook locations also adhering to its standards.
• The acquisition will provide a larger scale for negotiating with payers and improving cash flow for practices.

Negatives

• There is a risk that the acquisition may not be completed.
• The integration of Greenbrook and Neuronetics may present challenges.
• There is a risk that the expected benefits of the acquisition may not be fully realized.
• The company has a history of losses and may not achieve or sustain profitable operations.
• The company relies heavily on the sale and usage of the NeuroStar system for revenue.

Risks

• The acquisition may not be completed due to various factors, including failure to obtain necessary approvals.
• There is a risk of disruption to management's attention from ongoing business operations due to the acquisition.
• The announcement of the acquisition may negatively impact relationships with customers and operating results.
• There is a risk of legal proceedings related to the acquisition.
• The stock price of both companies may decline if the acquisition is not completed.
• The company's ability to achieve cash flow break-even in the fourth quarter of 2024 and on a full-year basis in 2025 is not guaranteed.
• The company faces risks related to competition, product defects, and intellectual property protection.
• The company's revenue is concentrated among a small number of customers.

Future Outlook

The company anticipates increased brand awareness and improved practice support through the acquisition of Greenbrook. They also aim to achieve cash flow break-even by the end of 2024 and on a full-year basis in 2025. The company plans to expand its services and offerings to practices.

Management Comments

• Keith Sullivan, CEO of Neuronetics, stated that the acquisition will help drive greater awareness and get to more patients.
• Bill Leonard, CEO of Greenbrook TMS, expressed excitement about the opportunity and the ability to share best practices.
• Keith Sullivan emphasized that the goal is to make NeuroStar a household name for patients battling depression.
• Bill Leonard highlighted the importance of referral networks and the ability to provide multiple treatment modalities.
• Keith Sullivan stated that the acquisition will help solve the pain points that customers talk about at NSU.

Industry Context

This acquisition reflects a trend in the mental health industry towards consolidation and the integration of different treatment modalities. It also highlights the importance of brand recognition and patient access in a competitive market. The move is similar to how Starbucks expanded its brand through brick-and-mortar stores and partnerships.

Comparison to Industry Standards

• The acquisition of Greenbrook by Neuronetics is a significant move in the TMS industry, as it combines the largest manufacturer with the largest provider.
• This is similar to other consolidations in the healthcare industry where companies seek to control more of the value chain.
• The focus on brand awareness and patient access is a common strategy among healthcare providers.
• The move to offer multiple treatment modalities (TMS, Spravato, medication management) is in line with the trend towards integrated care.
• The goal of achieving cash flow break-even is a common objective for companies in the growth phase.

Stakeholder Impact

• Shareholders of both Neuronetics and Greenbrook will be impacted by the acquisition.
• NeuroStar practices will benefit from improved services and support.
• Patients will have increased access to NeuroStar therapy.
• Employees of both companies will be affected by the integration.
• Payers will be impacted by the potential for new contracts and reimbursement rates.

Next Steps

• The companies will file preliminary and definitive joint proxy statements with the SEC and on SEDAR+.
• Greenbrook locations will be rebranded as NeuroStar centers.
• The companies will work to integrate their operations and services.
• NeuroStar will leverage Greenbrook's payer contracts to secure better reimbursement rates.
• Training will be provided to practices on incorporating Spravato and medication management.
• The companies will continue to develop and implement marketing strategies to increase brand awareness.

Key Dates

Keywords

Neuronetics, Greenbrook TMS, TMS, NeuroStar, Acquisition, Mental Health, Depression, Reimbursement, Spravato, Medication Management, Healthcare, Brand Awareness, Practice Management